Approach to a Patient with Acute kidney injury
-
Upload
calcutta-school-of-tropical-medicine-india -
Category
Health & Medicine
-
view
149 -
download
1
Transcript of Approach to a Patient with Acute kidney injury
![Page 1: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/1.jpg)
Approach to a patient with Acute
Kidney Injury
Dr. Sayan ChakrabortyJR-3, Dept. of Tropical Medicine,School of Tropical Medicine, KolkataEmail: [email protected]
![Page 2: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/2.jpg)
Epidemiology• 5-7% of acute care hospital admissions• 30% of ICU admissions with mortality rates –
50%• AKI worsens CKD• Severe AKI requiring dialysis increases risk of
developing dialysis-requiring-ESRD.• Community-acquired AKI: Volume depletion,
ADRs & obstruction of the urinary tract. • Hospital-acquired AKI: Sepsis, major surgical
procedures, heart or liver failure, IV iodinated contrast and nephrotoxic drugs
![Page 3: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/3.jpg)
AKI in Tropics
• Diarrhoeal diseases• Envenomations from snakes, spiders,
caterpillars, and bees• Malaria• Leptospirosis• Crush injuries from earthquakes and
resultant rhabdomyolysis
![Page 4: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/4.jpg)
Definition of AKI
![Page 5: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/5.jpg)
KDIGO criteria (ungraded)
• Increase in SCr by ≥0.3 mg/dl (≥26.5 umol/l) within 48 hours;
or• Increase in SCr to ≥1.5 times baseline,
which is known or presumed to have occurred within the prior 7 days;
or• Urine volume <0.5 ml/kg/h for 6 hours.
![Page 6: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/6.jpg)
KDIGO- Staging of AKI
![Page 7: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/7.jpg)
RIFLE Criteria
R iskI njuryF ailureL oss of functionE nd-Stage Renal
disease
![Page 8: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/8.jpg)
RIFLE Criteria
R isk
Increase in Cr of 1.5-2.0 X baseline or urine output < 0.5 mL/kg/hr for more than 6 hours.
I njury
F ailure
L oss of function
E nd-Stage Renal disease
![Page 9: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/9.jpg)
RIFLE Criteria
R isk: Inc Cr 50-100% or U.O. < 0.5 mL/kg/hr for more than 6 hrs
I njury• increase in Cr 2-3 X baseline (loss of 50% of GFR) or • urine output < 0.5 mL/kg/hr for more than 12 hours.
F ailure
L oss of function
E nd-Stage Renal disease
![Page 10: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/10.jpg)
RIFLE Criteria
R isk: Inc Cr 50-100% or U.O. < 0.5 mL/kg/hr for > 6 hrs
I njury: Inc Cr 100-200% or U.O. < 0.5 mL/kg/hr > 12 hrs
F ailure increase in Cr rises > 3X baseline Cr (loss of 75% of GFR)
or an increase in serum creatinine greater than 4 mg/dL, or urine output < 0.3 mL/kg/hr for more than 24 hours or
anuria for more than 12 hours.
L oss of function
E nd-Stage Renal disease
![Page 11: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/11.jpg)
RIFLE Criteria
R isk: Inc Cr 50-100% or U.O. < 0.5 mL/kg/hr for > 6 hrs
I njury: Inc Cr 100-200% or U.O. < 0.5 mL/kg/hr > 12 hrs
F ailure: Inc Cr > 200% or > 4 mg/dL or U.O. < 0.3 mL/kg/hr > 24 hrs or anuria for more than 12 hours
L oss of function persistent renal failure (i.e. need for dialysis) for
more than 4 weeks.
E nd-Stage Renal disease
![Page 12: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/12.jpg)
RIFLE Criteria
R isk: Inc Cr 50-100% or U.O. < 0.5 mL/kg/hr for > 6 hrs
I njury: Inc Cr 100-200% or U.O. < 0.5 mL/kg/hr > 12 hrs
F ailure: Inc Cr > 200% or > 4 mg/dL or U.O. < 0.3 mL/kg/hr > 24 hrs or anuria for more than 12 hours
L oss of function: Need for dialysis for more than 4 weeks
E nd-Stage Renal disease persistent renal failure (i.e. need for dialysis) for more
than 3 months.
![Page 13: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/13.jpg)
![Page 14: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/14.jpg)
Etiopathogenesis of
AKI
![Page 15: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/15.jpg)
Classification of AKIAcute Kidney Injury
Pre-renal Intrinsic Post-renal
Glomerular Interstitial VascularTubular
55% 40% 5%
85%10%<5% <5%
![Page 16: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/16.jpg)
![Page 17: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/17.jpg)
Pre-renal AKI
![Page 18: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/18.jpg)
![Page 19: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/19.jpg)
![Page 20: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/20.jpg)
![Page 21: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/21.jpg)
![Page 22: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/22.jpg)
![Page 23: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/23.jpg)
Non- oliguric AKI• Non- Oliguric: In hospital set-up, secondary
Nephrotoxic agents like:Aminoglycosides (10-30%), even in therapeutic
ranges, manifestation after 5-7 days of therapyAmphotericin B: Dose & duration dependent;
polyuria, hypomagnesemia, hypocalcemia, &nongap metabolic acidosis
• Non-oliguric has better prognosis than oliguric
one.
![Page 24: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/24.jpg)
ICU vs Non-ICU AKI
• Non-ICU AKI, kidney usually being the only failed organ, mortality rates of up to 10%.
• ICU AKI often associated with sepsis and
with non-renal multi-organ system failure, mortality rates of over 50%
![Page 25: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/25.jpg)
Diagnostic Evaluation History and Physical examination:• Pre-renal: History: vomiting, diarrhoea, glycosuria
causing polyuria, and several medications including diuretics, NSAIDs, ACE inhibitors, and ARBs.
Examination: Physical signs of orthostatic hypotension, tachycardia, reduced jugular venous pressure, decreased skin turgor, and dry mucous membranes are often present in prerenal azotemia
![Page 26: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/26.jpg)
Diagnostic EvaluationINTRINSIC RENAL:Review all medications • Cause of AKI .• Dose Adjustment.
Systemic vasculitis with Glomerulonephritis: • Palpable purpura• Pulmonary hemorrhage,• Sinusitis.
Atheroembolic • Livedo reticularis and other signs of emboli to the legs.• Rhabdomyolysis.• Signs of limb ischemia
![Page 27: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/27.jpg)
Diagnostic Evaluation• Post- Renal:Colicky flank pain radiating to the groin suggests
acute ureteric obstruction.
Nocturia and urinary frequency or hesitancy can be seen in prostatic disease.
Abdominal fullness and suprapubic pain can accompany massive bladder enlargement. Definitive diagnosis of obstruction requires radiologic investigations.
![Page 28: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/28.jpg)
Blood Tests
• CBC• BUN/creatinine • Electrolytes• Uric acid• PT/aPTT
![Page 29: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/29.jpg)
Urine Analysis
•Volume•Osmolality•Proteinuria•Urinary Indices: FeNa& Urinary Sodium •Sediments
![Page 30: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/30.jpg)
![Page 31: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/31.jpg)
Imaging
• Renal ultrasound (useful for obstructive forms)
• Doppler (to assess renal blood flow)• CT Scan • Pyelography• Nuclear Medicine Scans :
DMSA: anatomy. DTPA and MAG3: renal function,
urinary excretion and upper tract outflow.
![Page 32: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/32.jpg)
![Page 33: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/33.jpg)
Important biomarkers
•Cystatin C
•Neutrophil gelatinase-associated lipocalin (NGAL)
•Interleukin-18 •Kidney injury molecule-1
•N-acetyl-D-glucosaminidase
![Page 34: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/34.jpg)
![Page 35: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/35.jpg)
Cystatin-C
• Superior to serum creatinine, as a surrogate marker of early and subtle changes of kidney function.
• Identifies kidney injury while creatinine levels remain normal
• Allows detection of AKI, 24-48 hours earlier than serum creatinine
![Page 36: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/36.jpg)
Kidney Injury Molecule-1 (KIM-1)
• Type 1 trans-membrane glycoprotein
• Served as a marker of severity of AKI
• Can be used to predict adverse outcomes in hospitalized patients better than conventionally used severity markers.
![Page 37: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/37.jpg)
Neutrophil gelatinase-associated lipocalin(NGAL)
• Highly upregulated after inflammation and kidney injury
• Can be detected in the plasma & urine within 2 hours of cardiopulmonary bypass–associated AKI.
• Considered equivalent to troponin in acute coronary syndrome.
![Page 38: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/38.jpg)
Complications of AKI
![Page 39: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/39.jpg)
![Page 40: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/40.jpg)
Major causes of AKI in Specific
Clinical settings
![Page 41: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/41.jpg)
![Page 42: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/42.jpg)
![Page 43: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/43.jpg)
![Page 44: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/44.jpg)
Treatment of AKI
![Page 45: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/45.jpg)
General Issues
1. Optimization of systemic and renal hemodynamics through volume resuscitation and judicious use of vasopressors
2. Elimination of nephrotoxic agents (e.g., ACE inhibitors, ARBs, NSAIDs, aminoglycosides) if possible
3. Initiation of renal replacement therapy when indicated
![Page 46: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/46.jpg)
Pre-Renal AKI
• Prevention and treatment of prerenal azotemia requires optimization of renal perfusion.
• Severe acute blood loss should be treated with PRBC transfusion.
![Page 47: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/47.jpg)
FLUIDS• KDIGO advocates use of isotonic crystalloids
rather than colloids (albumin or starches) .
• Colloids may be chosen to avoid excessive fluid administration requiring large volume resuscitation, or in specific patient subsets (e.g., a cirrhotic patient with spontaneous peritonitis, or in burns).
• Colloids- Albumin is renoprotective and Hyperoncotic starch shows nephro- toxicity.
![Page 48: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/48.jpg)
Vasopressors
• Appropriate use of vasoactive agents improve kidney perfusion in volume-resuscitated patients with vasomotor shock.
• Dopamine associated with a greater number of adverse events than Nor-epinephrine.
![Page 49: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/49.jpg)
Low Dose Dopamine
• Its use has been abandoned by most subsequent to negative results of various studies .
• KDIGO recommends not using low-dose dopamine to prevent or treat AKI. (1A)
![Page 50: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/50.jpg)
Cirrhosis and Hepatorenal Syndrome
• Albumin may prevent AKI in those treated with antibiotics for SBP
• Bridge therapies [in combination with IV Inf albumin (25–50 mg/d)] include: terlipressin (a vasopressin analog), combination therapy with octreotide (a
somatostatin analog) and midodrine (an α 1-adrenergic agonist), and norepinephrine
![Page 51: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/51.jpg)
Cardio-Renal Syndrome
• Optimization of cardiac function .
• May require use of inotropic agentspreload- and afterload-reducing agents,antiarrhythmic drugs,mechanical aids such as an intra-aortic
balloon pump.
![Page 52: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/52.jpg)
Treatment of Intrinsic AKI
![Page 53: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/53.jpg)
Diuretic• Renoprotective : Potentially lessening ischemic injury
•Can also be harmful, by worsening established AKI.
• No evidence of incidence reduction.
• KDIGO recommend not using diuretics to prevent AKI
• KDIGO suggest not using diuretics to treat AKI, except in the management of volume overload
• Indicated only for management of fluid balance, hyperkalemia, and hypercalcemia.
![Page 54: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/54.jpg)
FENOLDOPAM
• Fenoldopam mesylate: pure dopamine type-1 receptor agonist
• Without systemic adrenergic stimulation.• No conclusive studies available.• For critically ill patients with impaired renal
function, a continuous infusion of fenoldopam 0.1mg/kg/min improves renal function when compared to low dose dopamine.
![Page 55: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/55.jpg)
Erythropoietin • Potential clinical benefit of erythropoietin in AKI in animal studies.
• Renoprotective action of erythropoietin related to pleomorphic properties including anti-apoptotic & anti-oxidative effects, stimulation of cell proliferation, and stem-cell mobilization.
• Although one recent RCT in the prevention of human AKI was negative, the usefulness of erythropoietin in human AKI should be further tested in RCTs.
![Page 56: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/56.jpg)
Growth factor intervention
• IGF-1 is a peptide with renal vasodilatory, mitogenic and anabolic properties.
• KDIGO Work Group recommends against its use in patients with AKI.
![Page 57: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/57.jpg)
Rhabdomyolysis
• Aggressive volume repletion (may require 10 L of fluid/day)
• Alkaline fluids beneficial
• Diuretics may be used if fluid repletion is adequate & no urine output
• Dialysis
• Focus on calcium and phosphate status because of precipitation in damaged tissue
![Page 58: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/58.jpg)
Glomerulonephritisor Vasculitis
• May respond to immunosuppressive agents and/or plasmapheresis
• Allergic interstitial nephritis due to medications requires discontinuation of the offending agent.
• Glucocorticoids have been used, but not tested in randomized trials. • AKI due to scleroderma (scleroderma renal crisis) should be treated with ACE inhibitors.
![Page 59: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/59.jpg)
Aminoglycoside Induced AKI
• KDIGO suggest not using aminoglycosides for the t/t of infections unless no suitable, less nephrotoxic, therapeutic alternatives are available
• Avoid in high risk patients of age > 65 years, DM, septic shock
• Single dose daily rather than multiple-dose daily t/t regimens
• Topical or local applications of aminoglycosides (e.g., respiratory aerosols, instilled antibiotic beads), rather than I.V. application, when feasible
![Page 60: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/60.jpg)
AMPHOTERICIN B NEPHROTOXICITY
• KDIGO suggest using lipid formulations of amphotericin B rather than conventional formulations
• Use azole antifungal agents and/or the echinocandins rather than conventional amphotericin B, if equal therapeutic efficacy can be assumed.
• Some studies indicate that the liposomal form of amphotericin B is less nephrotoxic than lipid complex or colloidal dispersion forms
![Page 61: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/61.jpg)
Post-renal
• Prompt relief of urinary tract obstruction.
• Relief of obstruction is usually followed by an appropriate diuresis and may require continued administration of IVF & electrolytes for a period of time.
![Page 62: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/62.jpg)
Indications for Dialysis
A – Acidosis E – Electrolyte disturb, usually
hyperkalemia I – Intoxications (lithium, ethylene glycol,
etc) O – Overload (volume overload) U – Uremia (symptoms, signs )
![Page 63: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/63.jpg)
Modes Of Dialysis
• Hemodynamically stable- IHD
• Hemodynamically unstable1. CRRT2. PD3. SLED
![Page 64: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/64.jpg)
Prognosis
• Pre-renal and Post- renal better prognosis.• Kidneys may recover even after dialysis
requiring AKI.• 10% of cases requiring dialysis develop
CKD.• Die early even after kidney function
recovers completely.
![Page 65: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/65.jpg)
Recent Publications
![Page 66: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/66.jpg)
Recent Publications
![Page 67: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/67.jpg)
• Diagnose early – Biomarkers have great potential
• Look for etiology• Prevent rather than treat• No role of low dose dopamine, diuretics in
prevention and treatment• Initiate RRT when indicated
![Page 68: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/68.jpg)
References• Brenner and Rector's The Kidney 9th ed. - M. Taal (Saunders,
2012) • Harrison's Principles of Internal Medicine, 19th edition (2015)• Paul Marino The ICU Book(3rd Ed)• The Washington manual of Critical care 2nd edition• Kidney Disease: Improving Global Outcomes (KDIGO) Acute
Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter., Suppl. 2012; 2: 1–138
• Rahman et al Acute kidney injury: A guide to diagnosis and management; American Family Physician, Volume 86, Number 7 October 1, 2012
• Ronco C Acute Kidney Injury: from clinical to molecular diagnosis; Ronco Critical Care (2016) 20:201
![Page 69: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/69.jpg)
![Page 70: Approach to a Patient with Acute kidney injury](https://reader035.fdocuments.net/reader035/viewer/2022062503/587b354a1a28ab057d8b6fb5/html5/thumbnails/70.jpg)